Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586531 | 0.88 | MMP13 (0.46) | MMP13HSD11B1GPR119KMT2AMEN1 | |
| SCHEMBL26143890 | 0.85 | MMP13 (0.43) | MMP13HSD11B1GPR119KMT2AMEN1 | |
| SCHEMBL23265405 | 0.84 | HSD11B1 (0.44) | MMP13HSD11B1GPR119KMT2AMEN1 | |
| SCHEMBL26361860 | 0.83 | MMP13 (0.45) | MMP13HSD11B1GPR119KMT2AMEN1 | |
| SCHEMBL323498 | 0.83 | MMP13 (0.43) | MMP13HSD11B1GPR119KMT2AMEN1 | |
| SCHEMBL26907154 | 0.83 | MMP13 (0.43) | MMP13HSD11B1GPR119KMT2AMEN1 | |
| SCHEMBL11995208 | 0.83 | MMP13 (0.43) | MMP13HSD11B1GPR119KMT2AMEN1 | |
| SCHEMBL23245584 | 0.83 | STAT3 (0.43) | KMT2AMEN1CYP2D6ENPP3ENPP1 | |
| SCHEMBL3973620 | 0.82 | HSD11B1 (0.49) | MMP13HSD11B1GPR119KMT2AMEN1 | |
| SCHEMBL12794680 | 0.82 | HSD11B1 (0.49) | MMP13HSD11B1GPR119KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| CN-112585132-B | Proteasome activity enhancing compounds | 优曼尼蒂公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | MMP13 2460/4885HSD11B1 2082/4885GPR119 1787/4885 |
| US-11560385-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | MMP13 2460/4885HSD11B1 2082/4885GPR119 1787/4885 |
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | MMP13 2460/4885HSD11B1 2082/4885GPR119 1787/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | MMP13 2460/4885HSD11B1 2082/4885GPR119 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.